Last update 31 Dec 2025

IASO 208

Overview

Basic Info

Drug Type
in vivo CAR-T therapy
Synonyms-
Target
CD20
Action
inhibitors
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
B-Cell Malignant NeoplasmAutoimmune DiseasesRefractory Multiple Myeloma+ [1]
Inactive Indication-
Originator Organization
Iaso Biotherapeutics Usa Ltd.Shanghai IASO Biotherapeutics Co., Ltd.
Active Organization
Iaso Biotherapeutics Usa Ltd.Shanghai IASO Biotherapeutics Co., Ltd.Nanjing IASO Biotherapeutics Co., Ltd.Nanjing IASO Biotherapeutics Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with IASO 208
NCT07309900
/ Not yet recruitingPhase 1IIT
A Single-arm, Open-label Exploratory Clinical Study of IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
100 Clinical Results associated with IASO 208
Login to view more data
100 Translational Medicine associated with IASO 208
Login to view more data
100 Patents (Medical) associated with IASO 208
Login to view more data
100 Deals associated with IASO 208
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell Malignant NeoplasmPhase 1
China
Nanjing IASO Biotherapeutics Co., Ltd.Nanjing IASO Biotherapeutics Co., Ltd.
15 Dec 2025
Autoimmune DiseasesPreclinical
United States
Iaso Biotherapeutics Usa Ltd.
06 Dec 2025
Autoimmune DiseasesPreclinical
China
Shanghai IASO Biotherapeutics Co., Ltd.
06 Dec 2025
Refractory Multiple MyelomaPreclinical
United States
Iaso Biotherapeutics Usa Ltd.
06 Dec 2025
Refractory Multiple MyelomaPreclinical
China
Shanghai IASO Biotherapeutics Co., Ltd.
06 Dec 2025
Relapse multiple myelomaPreclinical
United States
Iaso Biotherapeutics Usa Ltd.
06 Dec 2025
Relapse multiple myelomaPreclinical
China
Shanghai IASO Biotherapeutics Co., Ltd.
06 Dec 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free